• Someone Change The Channel

    by Mark Sales  |  Nov 3, 2017
    Our current multi-channel approaches for pharma are staid and in many cases just don't have an end point that makes business sense. We know that brand equity is not only linked to sales but to future performance of the brand. You can read more about this in our recent Edge of Insight Report, which details that 25% of brand equity is attributed to recent touchpoints, of which most of this is still due to the sales force.
  • Being able to link clinical data with the patient’s perspective opens up the possibilities of really understanding a disease. And, realizing the true impact of a disease, or how your medicine can cure a disease or help a patient live better with it, will usher in the new age of patient centricity.
  • The Patient's Voice on More than 200 Health Conditions

    by Michael Fronstin  |  Oct 9, 2017
    Michael Fronstin highlights disparities in health spending, outcomes and quality of life across major health markets in a review of new data from the National Health and Wellness Survey.
  • Getting Inside the Patient – Part 2

    by Tim Irfan  |  Oct 6, 2017
    This blog explains how to achieve success in ethnographic research studies, allowing pharmaceutical companies to approach the patient in a new way that's both meaningful and helpful to the patient and worthwhile for companies.
  • Results from three phase III trials of could change treatment practice, should be considered strong enough to convince physicians and their patients to increase use of adjuvant treatment. As these trials differed in their patient populations and offered differing efficacy/toxicity profiles, potential utilization of Tafinlar (dabrafenib, Novartis) with or without Mekinist (trametinib, Novartis) as well as Opdivo (nivolumab, Bristol-Myers Squibb / Ono Pharmaceuticals) will be discussed. It may not be as simple as “offer BRAF/MEK inhibition to BRAF mutant patients."
More than one Google Analytics scripts are registered. Please verify your pages and templates.